BoYuan RunSheng Pharma

BoYuan RunSheng Pharma is a clinical-stage biopharmaceutical company based in Beijing, China, dedicated to developing next-generation precision oncology therapies. The company specializes in the design and development of highly selective small molecule inhibitors targeting specific genetic drivers of cancer. Its lead program, BYR51, is a potent RET inhibitor currently in Phase 1/2 clinical trials for the treatment of RET-fusion positive non-small cell lung cancer and medullary thyroid cancer. Beyond its lead candidate, the company is advancing a pipeline of novel inhibitors designed to overcome clinical resistance mechanisms associated with first-generation targeted therapies. BoYuan RunSheng is supported by leading life science investors and focuses on delivering transformative treatments for patients with high unmet medical needs.